Analysis on the safety and impact of lactating women taking Bicnprenol tablets (Bituvi) on their babies

Biktarvy is an antiretroviral combination tablet that contains Bictegravir (Bictegravir), emtricitabine (Emt ricitabine) and tenofovir alafenamide (TAF), for the treatment of HIV infection in adults. Since its ingredients can reach a certain concentration in the blood, when using it during breastfeeding, special attention needs to be paid to whether the drug enters the baby's body through milk and the possible effects.

Clinical and pharmacokinetic studies have shown that ingredients in Biktarvy are secreted into breast milk in small amounts, but overall exposure is relatively low. However, since infants' liver and kidney functions are not fully mature and have limited ability to metabolize and excrete drugs, long-term or continuous intake may involve certain risks, such as a slight burden on liver function or potential effects on the immune system. Therefore, international guidelines generally recommend that nursing mothers weigh maternal and infant safety when using Biktarvy and choose alternative feeding methods if necessary.

For mothers who must breastfeed, if the doctor assesses that the mother's condition requires continued useBiktarvy, the baby's growth and development, liver and kidney function, and blood routine indicators should be regularly monitored. Parents should observe whether the baby has abnormal symptoms, such as loss of appetite, slow weight gain, indigestion or immune abnormalities, and report it to a pediatrician or infectious disease doctor in a timely manner. Scientific monitoring and early intervention can minimize potential risks.

In short, lactating women takingBiktarvy may have a certain risk of drug exposure to their babies, but short-term, low-dose intake is mostly controllable. Safety strategies include choosing alternative feeding when necessary, strictly following physician guidance, regularly monitoring the infant's health, and making individualized decisions after weighing the risks to mother and baby. Scientific management and continuous follow-up are key measures to ensure the safety of mothers and infants, and are also generally recommended methods in clinical practice.

Reference materials:https://www.drugs.com/